Want to see IN:EMCURE full AI Analyst Report?
EMCURE Stock Chart & Stats
₹1345.35
₹31.90(2.25%)
At close: 4:00 PM EST
₹1345.35
₹31.90(2.25%)
Day’s Range― - ―
52-Week Range₹1,230.00 - ₹1,944.00
Previous CloseN/A
Volume1.63K
Average Volume (3M)197.42K
Market Cap
₹348.20B
Enterprise Value₹341.03B
Total Cash (Recent Filing)₹6.02B
Total Debt (Recent Filing)₹16.59B
Price to Earnings (P/E)37.6
Beta0.80
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)22.89
Shares Outstanding189,659,550
10 Day Avg. Volume24,274
30 Day Avg. Volume197,417
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.11
Price to Sales (P/S)3.29
P/FCF Ratio61.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,100.00Price Target Upside56.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)60.78
Revenue Forecast (FY)₹104.32B
Bulls Say, Bears Say
Bulls Say
Revenue And Earnings GrowthSustained top-line expansion (FY2026 revenue growth) combined with strong EPS growth signals improving product adoption and commercialization. Over a multi-month horizon, this supports higher reinvestment capacity, strengthens negotiating power with partners, and underpins durable earnings quality.
Healthy Operating And Net MarginsConsistent mid‑teens operating margin and a solid net margin indicate structural profitability versus peers. This margin profile suggests effective cost controls and pricing power in branded and contract lines, providing a buffer for reinvestment and resilience across business cycles.
Conservative Leverage And Improving ROELow debt relative to equity and improved high‑teens ROE point to a strong capital structure and improving capital efficiency. This durability reduces refinancing risk, supports strategic investments or partnerships, and preserves flexibility for M&A or capex over coming months.
Bears Say
Weak Cash ConversionFCF covering ~58% of net income shows earnings are not fully translating into cash. That weak conversion constrains organic funding for capex, dividends or acquisitions, raising dependence on working‑capital management or external financing over the medium term.
Gross Margin VolatilityMaterial swings in gross margin reduce predictability of core profitability and complicate forecasting. Volatility can stem from mix shifts, price moves or one‑offs, making sustainable margin planning and long‑range budgeting more challenging for management and investors.
Competitive Intensity In GenericsOperating in branded generics and generic markets exposes the company to structural pricing pressure and aggressive competition. Over a 2–6 month horizon this can limit pricing flexibility, compress margins on commoditized products, and require ongoing brand or portfolio investment.
Emcure Pharmaceuticals Limited News
EMCURE FAQ
What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?
Emcure Pharmaceuticals Limited lowest stock price was ₹1230.00 and its highest was ₹1944.00 in the past 12 months.
What is Emcure Pharmaceuticals Limited’s market cap?
Emcure Pharmaceuticals Limited’s market cap is ₹348.20B.
When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?
Emcure Pharmaceuticals Limited’s upcoming earnings report date is Aug 18, 2026 which is in 47 days.
How were Emcure Pharmaceuticals Limited’s earnings last quarter?
Emcure Pharmaceuticals Limited released its earnings results on May 05, 2026. The company reported ₹14.1 earnings per share for the quarter, beating the consensus estimate of ₹13.6 by ₹0.5.
Is Emcure Pharmaceuticals Limited overvalued?
According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued.
Does Emcure Pharmaceuticals Limited pay dividends?
Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.21%. See more information on Emcure Pharmaceuticals Limited dividends here
What is Emcure Pharmaceuticals Limited’s EPS estimate?
Emcure Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emcure Pharmaceuticals Limited have?
Emcure Pharmaceuticals Limited has 189,659,550 shares outstanding.
What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?
Emcure Pharmaceuticals Limited reported an EPS of ₹14.1 in its last earnings report, beating expectations of ₹13.6. Following the earnings report the stock price went down -5.249%.
Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:EMCURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
EMCURE Stock 12 Month Forecast
Average Price Target
₹2,100.00
▲(56.09% Upside)
Technical Analysis
AstraZeneca Pharma India Limited
―
Eris Lifesciences Ltd
―
JB Chemicals & Pharmaceuticals Ltd.
―
Dr. Lal PathLabs Limited
―
PFIZER LIMITED
―